MicroMass Communications joins Ashfield

MicroMass designs solutions across all therapeutic areas that improve patient and health outcomes by changing patient and provider behaviour. These solutions are created bespoke to the needs of each of MicroMass’ pharmaceutical clients. As the role of patients in healthcare decision making expands, coupled with the ongoing shift to digital channels, demand from pharmaceutical companies for behavioural change and direct patient engagement capabilities is increasing. MicroMass generates the majority of its revenue from patient engagement and support programmes, with the remainder coming from HCP (healthcare professional) focused work. MicroMass’ behavioural change and patient support and adherence services, are highly complementary to the existing services provided by both the Ashfield Communications and Commercial & Clinical businesses. MicroMass employs more than 100 people at its headquarters in Cary, North Carolina. The existing management team, who have been with the business for more than 10 years, will remain with the business post acquisition. Commenting on the announcement, Brendan McAtamney, CEO of UDG Healthcare plc, said: “I am delighted to welcome MicroMass into the UDG Group. They have developed a highly-differentiated suite of patient and HCP solutions, with a strong reputation and a significant presence within the highly-fragmented healthcare communications market.  MicroMass provides the Group with the ability to strengthen Ashfield’s presence and ...
Source: Ashfield Healthcare News - Category: Pharmaceuticals Authors: Tags: Ashfield Source Type: news